Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Xarelto picture

NICE recommends Xarelto for stroke prevention

May 23, 2012
Sales and Marketing Bayer, DVT, NICE, Pradaxa, Xarelto, anticoagulant

NICE is recommending Bayer’s anticoagulant pill Xarelto to help reduce the risk of stroke in certain patients.  The watchdog’s final …

News
Andrew Lansley

NICE to be sidelined on cost effectiveness – once again

May 17, 2012
Sales and Marketing NICE, VBP

Health secretary Andrew Lansley has confirmed that NICE will no longer direct the NHS on the cost effectiveness of drugs. …

News
NICE image

NICE comes out fighting against appraisal delays story

May 17, 2012
Sales and Marketing Daily Mail, Dillon, NHS, NICE, Pfizer, Victrelis

NICE has criticised a report that says the watchdog has taken up to nine years to appraise certain drugs.   The …

News
Zytiga image

Price cut sways NICE on Zytiga

May 16, 2012
Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer

NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance.  In its final guidance, the watchdog is recommending …

News
yervoy image

Scottish watchdog rejects Yervoy

May 14, 2012
Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma

The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy.  The SMC said that Yervoy (ipilimumab), which has …

News
NICE image

NICE changes its mind on Botox

May 11, 2012
Sales and Marketing Allergan, Botox, NHS, NICE

NICE is now recommending Allergan’s Botox for chronic migraines, reversing its previous decision.  The watchdog said in final draft guidance …

News
Tarceva image

Discount sways NICE into recommending Tarceva

May 10, 2012
Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer

NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease.  The watchdog said …

News
Lucentis image

Novartis ponders Lucentis price cut in UK

May 8, 2012
Medical Communications, Sales and Marketing Lucentis, NICE, avastin, market access

 Novartis could cut the price of its eye drug Lucentis in the UK to head off moves to switch patients …

News
Benlysta image

NICE no to GSK’s lupus drug Benlysta

April 27, 2012
Sales and Marketing Andrew Dillon, Benlysta, GSK, Lupus, NICE

NICE is still not recommending GlaxoSmithKline’s lupus drug Benlysta, as it believes the treatment is too costly.  In its final …

News
Victrelis picture

Two new hep C pills recommended by NICE

April 25, 2012
Sales and Marketing Incivo, Janssen, MSD, NICE, Victrelis, hep C

NICE has given its final recommendation for two new hepatitis C pills in an expedited review.  Janssen’s Incivo (telaprevir) and …

News
NASS website

Abbott launches online tool for ankylosing spondylitis

April 23, 2012
Medical Communications AS, Abbott, NHS, NICE, ankylosing spondylitis

Abbott has launched a new online assessment tool that has the potential to change the landscape of ankylosing spondylitis (AS) …

News
avastin

NICE rejects Avastin for breast cancer

April 18, 2012
Sales and Marketing EMA, NICE, Roche, avastin, breast cancer

In a blow for Roche, NICE has turned down its cancer drug Avastin because of ‘too many uncertainties’ over cost …

News
Halaven image

NICE rejects Halaven for breast cancer

April 3, 2012
Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs.  In its final …

News
NICE image

NICE recommends Xgeva for bone metastasis

March 29, 2012
Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer

NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …

News
NICE hq pic

NICE looking into unlicensed and off-label drug use

March 26, 2012
Sales and Marketing DoH, NICE, off label, off-label, postcode, unlicensed

NICE is reviewing the use of off-label and unlicensed medicines across the NHS in England. This follows a pilot project …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026